

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

APC anti-T-bet

RRID:AB_10896913

Type: Antibody

Proper Citation

BioLegend Cat# 644813, RRID:AB_10896913

Antibody Information

URL: http://antibodyregistry.org/AB_10896913

Proper Citation: BioLegend Cat# 644813, RRID:AB_10896913

Target Antigen: T-bet

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: ICFC

Antibody Name: APC anti-T-bet

Description: This monoclonal targets T-bet

Target Organism: Human, Mouse

Clone ID: Clone 4B10

Antibody ID: AB_10896913

Vendor: BioLegend

Catalog Number: 644813

Alternative Catalog Numbers: 644814

Record Creation Time: 20231110T063640+0000

Record Last Update: 20260829T173101+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-T-bet.

No alerts have been found for APC anti-T-bet.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Dong P, et al. (2026) Enhanced HIF-1 α cooperation by a human ROR γ t mutant potentiates Th17 pathogenicity. Cell reports, 45(4), 117123.

Jelcic I, et al. (2025) T-bet⁺ CXCR3⁺ B cells drive hyperreactive B-T cell interactions in multiple sclerosis. Cell reports. Medicine, 6(3), 102027.

van der Heide V, et al. (2025) Prolonged but finite antigen presentation promotes reversible defects of "helpless" memory CD8⁺ T cells. Immunity, 58(7), 1742.

Braun LM, et al. (2025) Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer cell, 43(2), 269.

Lin M, et al. (2024) Inflammatory dendritic cells restrain CD11b⁺CD4⁺ CTLs via CD200R in human NSCLC. Cell reports, 43(2), 113767.

Wiede F, et al. (2022) PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity. Cancer discovery, 12(3), 752.

Webb ER, et al. (2022) Cyclophosphamide depletes tumor infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma. iScience, 25(9), 104995.

Ye L, et al. (2022) A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell metabolism, 34(4), 595.

Shemesh A, et al. (2022) Diminished cell proliferation promotes natural killer cell adaptive-like phenotype by limiting Fc γ RI α expression. The Journal of experimental medicine, 219(11).

Ren Z, et al. (2021) Gut microbiota-CRAMP axis shapes intestinal barrier function and immune responses in dietary gluten-induced enteropathy. EMBO molecular medicine, 13(8), e14059.

Si J, et al. (2020) Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies. Cancer cell, 38(4), 551.

Yadava K, et al. (2019) Natural Tr1-like cells do not confer long-term tolerogenic memory. *eLife*, 8.

Sivick KE, et al. (2018) Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity. *Cell reports*, 25(11), 3074.

Herndler-Brandstetter D, et al. (2018) KLRG1+ Effector CD8+ T Cells Lose KLRG1, Differentiate into All Memory T Cell Lineages, and Convey Enhanced Protective Immunity. *Immunity*, 48(4), 716.

Cuadrado E, et al. (2018) Proteomic Analyses of Human Regulatory T Cells Reveal Adaptations in Signaling Pathways that Protect Cellular Identity. *Immunity*, 48(5), 1046.

Uchimura T, et al. (2018) The Innate Immune Sensor NLRC3 Acts as a Rheostat that Fine-Tunes T Cell Responses in Infection and Autoimmunity. *Immunity*, 49(6), 1049.